过去一年中添加的文章，按日期排序
ARE ALECTINIB-INDUCED MYALGIA AND ELEVATION CREATINE PHOSPHOKINASE PREDICTORS OF HIGH RECURRECCE-FREE SURVIVAL?
OI Vynnychenko, RA Moskalenko - Art of Medicine, 2024 - art-of-medicine.ifnmu.edu.ua
11 天前 - … patients with non small cell lung cancer: A protocol for … Intracranial efficacy of alectinib
in ALK-positive NSCLC … with advanced ALK-positive non-small-cell lung cancer receiving …
in ALK-positive NSCLC … with advanced ALK-positive non-small-cell lung cancer receiving …
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
L Wu, Z Zou, Y Li, X Hao, J Ying, J Li, P Xing - Journal of Translational …, 2024 - Springer
20 天前 - … -small cell lung cancer (NSCLC) in 2007 [1], significant advancements have been
made in this field. Patients with advanced ALK-positive (ALK + ) NSCLC have experienced …
made in this field. Patients with advanced ALK-positive (ALK + ) NSCLC have experienced …
Cost-Effectiveness Analysis of 6 Tyrosine Kinase Inhibitors as First-Line Treatment for ALK-Positive NSCLC in China
M Zhang, B Zheng, W Yang, H Jiang… - Clinical Medicine …, 2024 - journals.sagepub.com
39 天前 - … untreated advanced ALK-positive NSCLC patients … rate compared with those
receiving crizotinib. In addition, … of lorlatinib for adult ALK-positive NSCLC patients who had …
receiving crizotinib. In addition, … of lorlatinib for adult ALK-positive NSCLC patients who had …
A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).
K Concannon, G Selvaggi, J Zhou, YY Elamin - 2024 - ascopubs.org
42 天前 - … chemotherapy and bevacizumab had an acceptable safety profile and demonstrates
clinical activity in treatment naïve and previously treated advanced ALK-positive NSCLC, …
clinical activity in treatment naïve and previously treated advanced ALK-positive NSCLC, …
[HTML][HTML] A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
S Kilickap, A Ozturk, N Karadurmus, T Korkmaz… - Medicine, 2024 - journals.lww.com
46 天前 - … cancer patients lost their lives in 2019. [ 1 ] This disease burden makes lung cancer
the leading cause of cancer … [ 2 ] About 85% of the lung cancer cases are histologically …
the leading cause of cancer … [ 2 ] About 85% of the lung cancer cases are histologically …
A Rare Case of Inflammatory Myofibroblastic Tumor Appearing Left Lower Lung
J Liu, S Ramineni, S Nisar - 2024 - dc.etsu.edu
98 天前 - … Chemotherapy may be an effective option for advanced IMT with sarcomatoid
features. Targeted therapy can be applied for ALK-positive … can be applied for ALK-positive IMT. …
features. Targeted therapy can be applied for ALK-positive … can be applied for ALK-positive IMT. …
Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity
MS von Itzstein, DE Gerber - Clinical chemistry, 2024 - academic.oup.com
132 天前 - … after crizotinib progression. While formally FDA approved only for ALK-positive lung
cancer, … for second-line therapy of ROS1-positive lung cancer (13). Notably, in the present …
cancer, … for second-line therapy of ROS1-positive lung cancer (13). Notably, in the present …
Identifying optimal ALK inhibitors in first-and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and …
153 天前 - … In total, 3474 ALK-positive NSCLC patients were included in this study. 10 RCTs
focused on first-line treatments, while the remaining assessed second-line treatments for …
focused on first-line treatments, while the remaining assessed second-line treatments for …
Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs …
C Yang, R Zeng, Y Zha, Y Li, T Wang, R Zhao… - Frontiers in …, 2024 - frontiersin.org
175 天前 - … of brain radiotherapy for lung cancer patients with brain … with advanced ALK-positive
NSCLC developed brain metastasis seven months after initiating treatment with crizotinib. …
NSCLC developed brain metastasis seven months after initiating treatment with crizotinib. …
P2. 01-02 Neoadjuvant Targeted Therapy for Resectable ALK-fusion Locally Advanced Non-small Cell Lung Cancer
D Zhao, N Wu - Journal of Thoracic Oncology, 2023 - jto.org
253 天前 - … Wu Peking University Cancer Hospital & Institute, Beijing/CN Introduction:
Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous entity with …
Locally advanced non-small cell lung cancer (NSCLC) is a highly heterogeneous entity with …